Blog
Revolutionizing EV Production: Immortalized hMSCs in Suspension!
**Excerpt:** π Discover how adapting immortalized hMSCs to suspension culture revolutionizes EV production, boosting scalability and reducing costs! ππ‘π¬
Conquering Contamination in Gene Therapy Production
π Overcoming sterility challenges in cell and gene therapy is vital! 𧬠Discover solutions for contamination risks and ensure quality! π¬π‘β¨
Agilent’s $925M Biovectra Buy: Boosting Growth!
Agilent is acquiring Biovectra for $925M! π° This deal enhances CDMO services, especially in mRNA and gene editing. ππ¦
Capra Biosciences wins $75M to solve pharmaceutical shortages
π Capra Biosciences awarded $7.5M project to scale and manufacture bio-derived small-molecule APIs, addressing ingredient shortages. π§ͺπ±π
Revolutionizing mRNA Vaccines: Faster Scalable and Effective!
π Advancing mRNA Vaccine and Therapy Development discusses progress in mRNA vaccines and therapies, highlighting cell-free cloning for gene synthesis. π§¬π
Mastering Automation: The Key to Scaling Cell and Gene Therapy
π¬ Learn from other industries! π Lack of scale-up expertise is a challenge for CGT manufacturers. βοΈ Master efficient manufacturing methods. π° Don't neglect late-stage trials and commercialization. π€ Hire experts. π€ Automation is crucial.
Revolutionizing Bioprocessing: Achieving Quality by Design
1. π± From Quality by Testing to Quality by Design: How the bioprocessing industry is embracing innovation for better efficiency and consistency. π 2. π The Ongoing Journey to Quality by Design: Integrating AI, IoT, and digital twin tech for improved bioprocessing outcomes. π
Revolutionary Open-Source Biomanufacturing Simulation Model!
π¬ A new open-source simulation model, KTB1, enables biomanufacturers to optimize continuous biomanufacturing processes with tailored strategies. π±
Breaking News: Gene Therapy Partnership Expands!
π’ Univercells Technologies and UPENN are expanding their partnership to evaluate gene therapy manufacturing scalability. π§ͺ The goal is accessibility and cost reduction. πͺππ¨βπ¬
Unlocking the Potential of Cell and Gene Therapies: The Game-Changing Solution
π§ͺ The cell and gene therapy market is growing rapidly, but development and manufacturing are complex. π SmartLabs offers a solution by hosting drug discovery, development, and manufacturing facilities in one location. π° This reduces costs and resources needed for non-scientific services, allowing companies to focus on developing robust processes. π‘ SmartLabs' modular facilities are customizable and phase-compliant, making it easier to transition through the drug development journey. π₯ Clients have access to expertise and support, and they retain control over their manufacturing process and IP. π¬ SmartLabs aims to accelerate scientific breakthroughs and adapt to the evolving life sciences industry.
